12.10.24 -- I Outsource, Reluctantly

The oligonucleotides sector is quickly evolving and seeing more industry partnerships than ever before. We caught up with DeciBio's Carl Schoellhammer and Phillip Leclair for their analysis.

Learn how the streamlined processes and reduced complexity enabled by a platform approach can lead to scalable manufacturing, rapid delivery, and expanded patient access for cell therapies.

Optimize your biopharmaceutical technology transfer by prioritizing clear communication, thorough training, and strategic planning to ensure success.

By implementing an efficient characterization strategy, researchers can enhance the consistency of allogeneic cell therapy starting material, ultimately leading to improved clinical outcomes.

mRNA therapy and vaccine manufacturing can become complex and challenging when working with multiple CMOs. Partnering with an end-to-end CMO is key to overcoming these hurdles.

Increased investment in allogeneic therapies and process-level advancements to achieve commercial scale are paving the way for streamlined, standardized cell therapy development and manufacturing.

As the field grows, understanding how to formulate RNA nanoparticles effectively is essential for advancing therapeutic innovations.

What sustainable manufacturing processes best address Oligonucleotide environmental impact while maintaining scalability?

This study used Oxford Nanopore Technologies' Direct RNA Sequencing Kit and obtained successful sizing of poly(A) tail regions. The results are presented in a histogram and table format.

See how this advanced SKPT-HEK293 4G9 was able to provide a robust, CGMP-ready solution for efficient viral vector production, supporting a range of AAV serotypes and CAR-T Lenti-viral vectors.

Allogeneic therapies are gaining popularity due to diversity, scalability, and affordability. A partner with innovative solutions can help streamline the path from discovery to commercialization.

Implementing NGS technology for adventitious virus testing in viral vector vaccine development and manufacturing is crucial for ensuring safety. Gain insights for an optimized sequencing method.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

For ATMP manufacturers seeking to expand operations across the EMEA region, understanding global trade and supply chain regulations is crucial.

Low AAV productivity and lack of platform processes continue to drive AAV production costs up. Explore a robust and scalable suspension manufacturing platform for AAV production.

For any biotherapeutic in development today, a critical element in achieving commercialization is reducing manufacturing risk.

Uncover how our collaborative approach positions us as an extended workbench for our partners, enabling faster, more effective solutions for patients.

Discover better logistics support for the pharmaceutical, biotechnology, and medical device industries with high-quality kit packing and distribution through in-house kit-building facilities. 

We navigate the rapidly evolving field of virotherapy to support the development and manufacturing of your gene therapies, viral vector vaccines, and oncolytic viruses (OVs).

Take advantage of a highly connected CDMO network that has the capabilities to ensure quality, speed, scalability, and flexibility. Learn more about the services available.

Leverage our flexible solutions and access to proprietary CHO-K1 cell lines in our state-of-the-art cGMP suites equipped with both single-use and traditional stainless steel bioreactors.

Codex HiCap RNA Polymerase delivers enhanced safety, cost-effectiveness, and performance, empowering researchers to unlock the full potential of mRNA therapeutics.

Katie Jorgensen introduces ElevateBio BaseCamp's path to commercial readiness in cell therapy, highlighting key strategies for scaling from clinical to commercial manufacturing.

Learn how leveraging a GMP-like environment even in early R&D stages is crucial for setting your cell therapy up for success as you advance toward IND and NDA approvals.